Hemosiderin and reticuloendothelial system proteins

Hemosiderin is an intracellular, insoluble iron-storage complex primarily composed of ferritin, denatured ferritin, and other proteinaceous and lipid components. It is predominantly found within the macrophages of the reticuloendothelial system (RES), including the liver (Kupffer cells), spleen, and bone marrow, where it serves as a long-term reservoir for iron that is less readily available than that in soluble ferritin (StatPearls, 2023). In pathological states such as hereditary hemochromatosis or chronic blood transfusions, hemosiderin accumulates excessively, leading to tissue damage and organ dysfunction through the generation of reactive oxygen species (NIH, 2022). While not a single molecular target like a receptor or enzyme, the iron sequestered within hemosiderin and associated RES proteins is the primary focus of iron chelation therapy. Drugs such as deferoxamine and deferasirox interact with these stores by binding ferric iron to form stable, excretable complexes, thereby reducing systemic iron burden and preventing organ failure (PubChem, 2024). Consequently, the term 'Hemosiderin and reticuloendothelial system proteins' describes a physiological compartment and pathological aggregate rather than a discrete, singular therapeutic protein (PubMed, 2021).

Other names

HemosiderinRES iron storesSiderinMononuclear phagocyte system iron proteinsIntracellular iron-storage complex

Iron chelation: These agents bind to ferric iron (Fe3+) within hemosiderin and ferritin complexes to form stable, non-toxic chelates that are subsequently excreted from the body via the kidneys or bile (PubChem, 2024).